Feb 12, 2020 | News
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2020 – T3D Therapeutics, Inc. (“T3D” ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today...
Feb 11, 2020 | News
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2020 – T3D Therapeutics, Inc. (“T3D” ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today...
Nov 6, 2019 | News
T3D Therapeutics is now fully funded to initiate the Phase 2 PIONEER Study of T3D-959 in Mild-to-Moderate Alzheimer’s Disease Patients RESEARCH TRIANGLE PARK, N.C., Nov. 4, 2019 — T3D Therapeutics, a clinical stage drug development company engaged in the...
May 20, 2019 | News
Research Triangle Park, NC, May 20, 2019 — T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959 (the “Company”), a new orally administered treatment for Alzheimer’s disease (AD), announced today that it has received a grant...
Jul 22, 2018 | News
T3D Therapeutics, Inc. today announced that final Phase 2a data with T3D-959 in mild to moderate Alzheimer’s disease subjects were presented in a session at the 2018 Alzheimer’s Association International Conference (AAIC) entitled ‘Novel Therapeutic Approaches for...
Mar 12, 2018 | News
T3D Therapeutics, Inc. today announced that FDG-PET neuroimaging data from a Phase 2a trial with T3D-959 in mild to moderate Alzheimer’s disease subjects were presented in an oral and poster presentation entitled ‘A Neurometabolic Approach to Treating Alzheimer’s...
